Ledraxen (Enoxaparin Sodium)

Enoxaparin sodium binds to antithrombin III, markedly enhancing its ability to inhibit factor Xa and, to a lesser extent, thrombin (factor IIa). This selective inhibition reduces the generation of thrombin and fibrin, thereby limiting clot formation while preserving normal hemostasis.

The dose of Ledraxen is individualized by the prescribing clinician based on the specific indication, patient weight, renal function, and treatment setting. Dosage regimens are determined by the treating physician and should follow local clinical guidelines.

Ledraxen is classified as Pregnancy Category B, indicating that animal studies have not shown risk but there are no adequate human studies. It should be used in pregnancy only if clearly needed. Limited data exist for breastfeeding; the decision should weigh potential benefits against possible risks.

To order Ledraxen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Compared with unfractionated heparin, enoxaparin (Ledraxen) offers more predictable pharmacokinetics, a longer half‑life, and a lower risk of heparin‑induced thrombocytopenia. Direct oral anticoagulants provide oral dosing but lack the reversibility and monitoring options that injectable low molecular weight heparins like Ledraxen offer in certain clinical settings.

Ledraxen should be stored at 2‑8 °C, protected from light, and must not be frozen. Keep the product in its original packaging to maintain stability. If the temperature rises above the recommended range, discard the solution to avoid reduced efficacy.

Ledraxen is administered by subcutaneous injection, intravenous infusion, or via the haemodialysis circuit, depending on the clinical indication. The injection site should be rotated for subcutaneous use, and aseptic technique must be observed for all routes.

The most serious risks include major bleeding events such as intracranial or gastrointestinal hemorrhage, and heparin‑induced thrombocytopenia (HIT), which can paradoxically cause new clot formation. Prompt recognition of these complications and immediate medical attention are essential.

Ledraxen should be avoided in patients with active major bleeding, known hypersensitivity to enoxaparin or heparin products, severe uncontrolled hypertension, or a history of HIT. Caution is also advised for individuals with significant renal impairment unless dose adjustments are made.